Protocol Ledger

NCT07470879 · Phase II · RECRUITING

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

Interventional Phase II clinical trial protocol NCT07470879 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-28 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07470879
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07470879
Protocol FieldVerified Registry Value
NCT IdentifierNCT07470879
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2026-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07470879
Hospital Research SiteLocationSite Profile
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
Monash HealthClayton, AustraliaOpen Hospital Dossier ->
University of AlbertaEdmonton, CanadaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI